At the time of writing, Corcept Therapeutics Inc [CORT] stock is trading at $74.28, up 4.06%%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The CORT shares have gain 6.02% over the last week, with a monthly amount drifted -2.01%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Corcept Therapeutics Inc [NASDAQ: CORT] stock has seen the most recent analyst activity on November 06, 2023, when Truist upgraded its rating to a Buy and also boosted its price target to $38 from $29. Previously, SVB Securities started tracking the stock with Market Perform rating on April 11, 2023, and set its price target to $25. On April 04, 2023, Piper Sandler initiated with a Overweight rating and assigned a price target of $27 on the stock. Jefferies downgraded its rating to a Hold and decreased its price target to $22 on February 15, 2023. Truist downgraded its rating to a Hold but $30 remained the price target by the analyst firm on August 01, 2022. Jefferies upgraded its rating to Buy for this stock on July 27, 2022, and upped its price target to $35.
For the past year, the stock price of Corcept Therapeutics Inc fluctuated between $29.18 and $117.33. Currently, Wall Street analysts expect the stock to reach $140 within the next 12 months. Corcept Therapeutics Inc [NASDAQ: CORT] shares were valued at $74.28 at the most recent close of the market. An investor can expect a potential return of 88.48% based on the average CORT price forecast.
Analyzing the CORT fundamentals
According to Corcept Therapeutics Inc [NASDAQ:CORT], the company’s sales were 685.45M for trailing twelve months, which represents an 7.09% jump. Gross Profit Margin for this corporation currently stands at 0.98% with Operating Profit Margin at 0.16%, Pretax Profit Margin comes in at 0.2%, and Net Profit Margin reading is 0.19%. To continue investigating profitability, this company’s Return on Assets is posted at 0.16, Equity is 0.2 and Total Capital is 0.16. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 72.05 points at the first support level, and at 69.83 for the second support level. However, for the 1st resistance point, the stock is sitting at 75.45, and for the 2nd resistance point, it is at 76.63.
Ratios To Look Out For
It is important to note that Corcept Therapeutics Inc [NASDAQ:CORT] has a current ratio of 3.07. In addition, the Quick Ratio stands at 2.96 and the Cash Ratio stands at 0.63. Considering the valuation of this stock, the price to sales ratio is 11.49, the price to book ratio is 11.52 and price to earnings (TTM) ratio is 64.47.
Transactions by insiders
Recent insider trading involved Robb Gary Charles, Chief Business Officer, that happened on Jun 16 ’25 when 3185.0 shares were sold. Officer, Robb Gary Charles completed a deal on Jun 16 ’25 to buy 3185.0 shares. Meanwhile, Director Swisher Daniel N JR sold 2200.0 shares on Jun 10 ’25.
